Some genetic disorders are caused by an accumulation of the mutated protein, with hereditary ATTR amyloidosis (hATTR) being a prime example. Therapeutic strategies that target these toxic aggregates are being tested in clinical trials. CENTOGENE’s active contributions to this field are demonstrated by a recent publication on the epidemiology of hATTR in the Journal of Clinical Medicine.
Some genetic disorders are caused by an accumulation of the mutated protein, with hereditary ATTR amyloidosis (hATTR) being a prime example. Therapeutic strategies that target these toxic aggregates are being tested in clinical trials. CENTOGENE’s active contributions to this field are demonstrated by a recent publication on the epidemiology of hATTR in the Journal of Clinical Medicine.
Read publication
